About Perdaman Pharmaceuticals Private Limited
Data last updated:
Perdaman Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 March 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24233DL2008PTC174864. Its GSTIN is 07AAFCP5941H1ZA (Delhi). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.03 Cr. It was formerly known as Perdaman Financial Services and Holdings Private Limited. It is led by directors including Vikas Rambal and Manoj Kumar Rambal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2024. The registered office is at N – 9 Ground Floor Panchsheel Park, New Delhi, Delhi, India – 110017.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.76 Cr, a growth of 4% compared to the previous year. For the same year it recorded a net profit of ₹21.85 Lakh (net margin 0.8%) and EBITDA of ₹2.63 Cr (EBITDA margin 9.1%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 10% over five years.
Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Sunrise International Labs. The company has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Curehealth Pharmaceuticals Private Limited with revenue of ₹29.03 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website perdaman.com.au.
CIN History of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals has one previous CIN (Corporate Identification Number): U65910DL2008PTC174864. The current CIN is U24233DL2008PTC174864, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24233DL2008PTC174864 | Current |
| U65910DL2008PTC174864 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressN – 9 Ground Floor Panchsheel Park, New Delhi, Delhi, India – 110017
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals operates one associated brand: Sunrise International Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Specializes in branded generics, formulations, and OTC drugs for pharmaceutical markets. | sunriseinternationallabs.com |
Business Activity of Perdaman Pharmaceuticals Private Limited
The main business activity of Perdaman Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Perdaman Pharmaceuticals Private Limited FY 2024 filings available
Perdaman Pharmaceuticals Private Limited reported revenue of ₹28.76 Cr (up 4% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Perdaman Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 4% growth in the latest year. EBITDA fell 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Perdaman Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹2.63 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹21.85 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Perdaman Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Perdaman Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals has 5 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Rambal Also directs: Shirdi Bio Fuels Private Limited, Sunrise International Labs Limited, Perdaman Renewable Energy Private Limited and 3 more | Director | 01 Dec 2015 | 10 Years 10 Months | Current |
| Manoj Kumar Rambal Also directs: Sunrise International Labs Limited | Director | 15 May 2010 | 16 Years 5 Months | Current |
| Usha Rambal | Director | 14 Oct 2010 | 16 Years 0 Months | Current |
| Samir Madhukar Garud Also directs: Sunrise International Labs Limited | Director | 20 Jun 2013 | 13 Years 4 Months | Current |
| Sarojni Rambal Also directs: Shirdi Bio Fuels Private Limited | Director | 24 Jan 2017 | 9 Years 8 Months | Current |
Peer Comparison of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Curehealth Pharmaceuticals Private Limited | ₹29.03 Cr (FY 2024) | •••• | •••• | 47.0% | •••• | Chandigarh, India |
| Monique Pharmaceuticals Private Limited | ₹28.97 Cr (FY 2024) | •••• | •••• | -51.0% | •••• | New Delhi, Delhi, India |
| Prowell Lifesciences Private Limited | ₹28.95 Cr (FY 2025) | •••• | •••• | 101.0% | •••• | Faridabad, Haryana, India |
| Stantech Pharmaceuticals Private Limited | ₹28.91 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Mumbai, Maharashtra, India |
| Dycine Pharmaceuticals Limited | ₹28.83 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Noida, Uttar Pradesh, India |
| Perdaman Pharmaceuticals Private Limited this company | ₹28.76 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | New Delhi, Delhi, India |
| Torino Laboratories Private Limited | ₹28.73 Cr (FY 2025) | •••• | •••• | 156.0% | •••• | Mumbai, Maharashtra, India |
| Goldfish Pharma Private Limited | ₹28.71 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Hyderabad, Telangana, India |
| Ceego Labs Private Limited | ₹28.61 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Chennai, Tamil Nadu, India |
| Texas Lifesciences Private Limited | ₹28.6 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Ahmedabad, Gujarat, India |
| Ives Drugs ( India) Pvt.Ltd. | ₹28.6 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | Indore, Madhya Pradesh, India |
Peers are the five companies nearest above and the five nearest below Perdaman Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals Private Limited is audited by Lavlesh & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Lavlesh & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Perdaman Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals Private Limited has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2018 | Rights issue | ₹2.03 Cr | Investors: Global Tech Consulting & Trading Pte Limited |
| Dec 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Oct 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Jul 2013 | Funding round | ₹9.99 Cr | Investors: 3 individuals |
Full deal history
All 6 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Perdaman Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Perdaman Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sunrise International Labs Limited | U24239TG1993PLC015367 | Locked |
Showing major subsidiaries. Total: 1.
Recent Activity on Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals Private Limited has 9 board changes on record since 2010: 5 appointments and 4 cessations. The latest: Manish Kumar Gupta ceased to be Company Secretary on 31 May 2022.
Credit Ratings, Litigation & Regulatory Alerts for Perdaman Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Perdaman Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Perdaman Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAFCP5941H1ZA | Delhi | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Perdaman Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 March 2008 (18+ years old) and is registered under CIN U24233DL2008PTC174864.
Perdaman Pharmaceuticals reported revenue of ₹28.76 Cr for FY 2025 (up 4% YoY).
Perdaman Pharmaceuticals has 5 current directors:
- Vikas Rambal - Director
- Manoj Kumar Rambal - Director
- Usha Rambal - Director
- Samir Madhukar Garud - Director
- Sarojni Rambal - Director
Perdaman Pharmaceuticals reported a net profit of ₹21.85 Lakh (net margin 0.8%) and EBITDA of ₹2.63 Cr (EBITDA margin 9.1%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Perdaman Pharmaceuticals is 1% over three years and 10% over five years. In the latest year (FY 2025) revenue rose 4%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Perdaman Pharmaceuticals is 07AAFCP5941H1ZA, registered in Delhi. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Perdaman Pharmaceuticals is U24233DL2008PTC174864. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Perdaman Pharmaceuticals was incorporated on 04 March 2008, making it 18+ years old. It is registered with the Registrar of Companies, Delhi.
Perdaman Pharmaceuticals has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018.
The peers of Perdaman Pharmaceuticals by revenue are Curehealth Pharmaceuticals Private Limited, Monique Pharmaceuticals Private Limited, Prowell Lifesciences Private Limited, Stantech Pharmaceuticals Private Limited, Dycine Pharmaceuticals Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Manish Kumar Gupta ceased to be Company Secretary on 31 May 2022. Sarojni Rambal was appointed as Director on 24 Jan 2017. Indeevar Kaul ceased to be Director on 01 Jan 2017. Perdaman Pharmaceuticals has 9 board changes on record in total.